HUTCHMED (HCM) News Today $16.09 +0.21 (+1.32%) As of 09:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HCM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in ChinaAugust 19 at 8:00 PM | globenewswire.comHUTCHMED (NASDAQ:HCM) Stock Rating Lowered by Wall Street ZenAugust 19 at 2:59 AM | americanbankingnews.comHUTCHMED (NASDAQ:HCM) Rating Lowered to Hold at Wall Street ZenAugust 18 at 2:48 AM | marketbeat.comHUTCHMED (NASDAQ:HCM) Cut to Buy at Wall Street ZenAugust 12, 2025 | americanbankingnews.comHUTCHMED (NASDAQ:HCM) Downgraded by Wall Street Zen to BuyAugust 10, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's What HappenedAugust 9, 2025 | marketbeat.comHUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Shares Bought by XY Capital LtdAugust 9, 2025 | marketbeat.comHUTCHMED (China) First Half 2025 Earnings: EPS: US$0.53 (vs US$0.03 in 1H 2024)August 9, 2025 | finance.yahoo.comHUTCHMED (NASDAQ:HCM) Trading Down 9.7% - Time to Sell?August 8, 2025 | marketbeat.comHUTCHMED (China) Limited (HCM) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Should You Buy?July 30, 2025 | marketbeat.comAllianz Asset Management GmbH Lowers Holdings in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM)July 26, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Stock Rating Upgraded by Wall Street ZenJuly 26, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Price Target Raised to $28.00 at Bank of AmericaJuly 22, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volume - What's Next?July 9, 2025 | marketbeat.comHUTCHMED to Announce 2025 Half-Year Financial ResultsJuly 3, 2025 | globenewswire.comHUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor TherapyJune 30, 2025 | globenewswire.comHUTCHMED (NASDAQ:HCM) Upgraded by Wall Street Zen to "Strong-Buy" RatingJune 27, 2025 | marketbeat.comHUTCHMED (China) Limited (HCM.L) - Yahoo FinanceJune 26, 2025 | nz.finance.yahoo.comHUTCHMED (China) Limited (HCM) - Yahoo FinanceJune 26, 2025 | au.finance.yahoo.comHow Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52% - NasdaqJune 25, 2025 | nasdaq.comPaycom Software: Automating Payroll And HCM Solutions; Initiate With 'Buy'June 22, 2025 | seekingalpha.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - Time to Sell?June 17, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Downgraded to "Buy" Rating by Wall Street ZenJune 14, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?June 12, 2025 | marketbeat.comHutchmed introduces new share options and LTIP awardsJune 11, 2025 | uk.investing.comHUTCHMED Grants Share Options and LTIP Awards to Boost Talent RetentionJune 10, 2025 | tipranks.comChina accepts NDA for sintilimab and fruquintinib combo in kidney cancerJune 4, 2025 | msn.comInnovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell CarcinomaJune 4, 2025 | prnewswire.comHUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell CarcinomaJune 4, 2025 | globenewswire.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Still a Buy?June 3, 2025 | marketbeat.comHUTCHMED’s SACHI Phase III Study Shows Promising Results for Lung Cancer TreatmentJune 1, 2025 | tipranks.comHUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual MeetingJune 1, 2025 | globenewswire.comMillennium Management LLC Sells 100,366 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)June 1, 2025 | marketbeat.comTrinity Delta Estimates HUTCHMED FY2025 EarningsMay 31, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Trims Position in HUTCHMED (China) Limited (NASDAQ:HCM)May 27, 2025 | marketbeat.comBNP Paribas Financial Markets Trims Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM)May 26, 2025 | marketbeat.comHUTCHMED to Present Promising Oncology Data at 2025 ASCO MeetingMay 22, 2025 | tipranks.comHUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual MeetingMay 22, 2025 | globenewswire.comJane Street Group LLC Grows Position in HUTCHMED (China) Limited (NASDAQ:HCM)May 22, 2025 | marketbeat.comHUTCHMED Successfully Passes All Resolutions at 2025 AGMMay 13, 2025 | tipranks.com18,102 Shares in HUTCHMED (China) Limited (NASDAQ:HCM) Acquired by Marshall Wace LLPMay 7, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Trading 3.9% Higher - Here's WhyApril 30, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Down 5.7% - Should You Sell?April 27, 2025 | marketbeat.comRenaissance Technologies LLC Has $2.72 Million Holdings in HUTCHMED (China) Limited (NASDAQ:HCM)April 27, 2025 | marketbeat.comHUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025April 23, 2025 | globenewswire.comHUTCHMED Completes Enrollment for Savolitinib Phase II Study in Gastric CancerApril 21, 2025 | tipranks.comHUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in ChinaApril 21, 2025 | globenewswire.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - What's Next?April 17, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Trading Up 6.9% - Time to Buy?April 16, 2025 | marketbeat.com Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address HCM Media Mentions By Week HCM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HCM News Sentiment▼-0.030.50▲Average Medical News Sentiment HCM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HCM Articles This Week▼33▲HCM Articles Average Week Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies QGEN News MRNA News BBIO News VRNA News ELAN News BPMC News ROIV News GRFS News LEGN News RVMD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HCM) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access